Cara Therapeutics to Present at Upcoming Investor Conferences
November 09 2021 - 4:30PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that Christopher
Posner, President and Chief Executive Officer, will participate in
the following upcoming investor conferences in November:
Stifel 2021 Virtual Healthcare
Conference, November 15, 2021 – November 17, 2021Fireside
Chat on Monday, November 15, 2021 at 1:20 p.m. ET
Jefferies London Healthcare Conference,
November 16, 2021 – November 19, 2021Fireside Chat on
Thursday, November 18, 2021 at 3:00 a.m. ET
Webcasts of the fireside chats can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com.
Archived webcast recordings will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral KORs. Cara is developing a novel and
proprietary class of product candidates, led by KORSUVA™
(CR845/difelikefalin), a first-in-class KOR agonist that targets
the body’s peripheral nervous system, as well as certain immune
cells. KORSUVA injection was approved by the FDA for the treatment
of moderate-to-severe CKD-aP in adults undergoing hemodialysis on
August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the
treatment of pruritus in patients with CKD and AD and is currently
in Phase 2 trials in PBC and NP patients with moderate-to-severe
pruritus.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024